ResMed (RMD) Expected to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is anticipated to release its Q4 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $2.89 per share and revenue of $1.4613 billion for the quarter. Individuals can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

ResMed Stock Up 3.5%

RMD stock opened at $222.81 on Wednesday. The firm has a market cap of $32.32 billion, a PE ratio of 21.49, a PEG ratio of 1.31 and a beta of 0.76. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The firm’s 50 day moving average price is $199.30 and its 200-day moving average price is $222.80. ResMed has a one year low of $180.26 and a one year high of $293.81.

Insider Activity

In other news, CEO Michael J. Farrell sold 4,991 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company’s stock, valued at approximately $101,893,036.65. This trade represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 14,973 shares of company stock worth $3,096,067 over the last 90 days. 0.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ResMed

Several institutional investors have recently modified their holdings of RMD. Jones Financial Companies Lllp boosted its holdings in ResMed by 52.6% in the first quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock valued at $645,000 after purchasing an additional 994 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in ResMed during the 2nd quarter worth about $389,000. Brown Advisory Inc. raised its position in ResMed by 17.8% in the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock valued at $409,000 after purchasing an additional 240 shares in the last quarter. Cresset Asset Management LLC acquired a new stake in ResMed in the 2nd quarter valued at about $206,000. Finally, Alliancebernstein L.P. boosted its stake in shares of ResMed by 24.2% in the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock valued at $73,808,000 after buying an additional 55,790 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

Analysts Set New Price Targets

RMD has been the subject of several recent analyst reports. Morgan Stanley reissued an “equal weight” rating and set a $230.00 target price (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Evercore set a $255.00 price target on ResMed and gave the stock an “outperform” rating in a report on Monday, April 13th. Jefferies Financial Group lowered their price target on ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a report on Friday, July 10th. Mizuho reduced their price objective on shares of ResMed from $235.00 to $220.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. began coverage on shares of ResMed in a research report on Wednesday, April 15th. They issued an “overweight” rating on the stock. Seven analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, ResMed presently has an average rating of “Hold” and an average target price of $246.25.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.